Contact
About
Mountarico develops GLP-1 therapies with a strong commitment to clinical research.
Mountarico was built to deliver consistent results through deep expertise and careful execution.
We align strategy with day-to-day operations so clients experience clarity at every step.
Our teams stay close to the work, combining proactive communication with practical problem solving.
Integrity, accountability, and clear communication guide every decision we make.
We believe in long-term partnerships, measurable outcomes, and consistent execution.
Clear ownership and transparent communication.
Thoughtful execution tailored to your needs.
Collaborative support across every milestone.
Experienced pharmaceutical leadership focused on advancing GLP-1 therapies with rigor, access, and patient-centered innovation.
Julia brings two decades in pharmaceutical development, leading GLP-1 programs from early research through commercialization. She has guided cross-functional teams in clinical strategy, regulatory engagement, and patient access, with a focus on durable outcomes in metabolic health.
Mark joins Mountarico from global banking and healthcare finance, where he led capital strategy, risk management, and funding for life sciences portfolios. He focuses on sustainable growth, disciplined investment, and long-term value creation.
Sandra builds high-performing teams for regulated, research-driven organizations. She is known for leadership development, inclusive talent pipelines, and scaling culture as R&D portfolios expand across clinical and commercial milestones.